ASNDAscendis Pharma A/Svs its industry peers
A metric-by-metric comparison of Ascendis Pharma A/S against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASND본 종목 | $15.3B#2 | — | — | — | — | — | — | — | — | — | 25.7%#3 | — |
| ADXN | $495M#6 | — | — | — | — | — | — | — | — | — | -66.6%#6 | — |
| AKTX | $1.62T#1 | — | 86904.8x#3 | 4392758.3x#3 | -39.5%#4 | 12.6%#3 | -4695.9%#3 | -93.0%#3 | -155.6%#1 | — | -66.4%#5 | — |
| ALMS | $1.0B#4 | — | 2.2x#1 | 41.6x#1 | — | 17.3%#2 | -1886.9%#2 | -53.8%#2 | — | — | 91.0%#1 | — |
| ATAI | $2.7B#3 | — | 15.5x#2 | 666.6x#2 | 1227.6%#1 | -342.2%#5 | -15751.1%#5 | -374.2%#4 | -2107.6%#2 | — | 59.4%#2 | — |
| ATHE | $800M#5 | — | — | — | — | — | — | — | — | — | -20.0%#4 | — |
| AXIM | — | — | — | — | 434.2%#2 | -191.7%#4 | -6961.0%#4 | — | — | — | — | — |
| AZN | — | — | — | — | 8.6%#3 | 45.3%#1 | 23.4%#1 | 21.0%#1 | — | — | — | — |
| BCTX | $31M#7 | — | — | — | — | -449.1%#6 | — | — | — | — | — | — |
| BCTXL | $8M#8 | — | — | — | — | -449.1%#6 | — | — | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice